Norway· NO-ID_1E13C400-1E62-4559-871E-158B0CA07C1E
Rubraca
A rucaparib product containing rucaparib, registered in Norway by pharmaand GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Rucaparib is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XK03 (rucaparib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Rucaparib · ATC L01XK03
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of rucaparib costs, country by country.
Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rucaparib · price per daily dose (1.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$240.27
The record
At a glance
FEST (Norway)- Active substance
- Rucaparib
- Manufacturer
- pharmaand GmbH
- Country
- Norway (NO)
- ATC code
- L01XK03
- ATC class
- Rucaparib
- Defined daily dose
- 1.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_1E13C400-1E62-4559-871E-158B0CA07C1E
- no_varenummer48678660NOK 46043.6
- gtin9120099676250
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
692 interactions on record for rucaparib.
Graded by severity as the source publishes them — 103 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rucaparib · interactions on record
692 records
- 103 severe
- 576 moderate
- 13 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- LonafarnibA16AX20severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rucaparib in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandRubraca 250 mg, Filmtablettenmmpharm GmbH
- SpainRUBRACA 250 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPharmaand Gmbh
- NetherlandsRubraca 250 mg, filmomhulde tablettenzr pharma& GmbH
- PolandRubracapharmaand GmbH
- SwedenRubraca 250 mg Filmdragerad tablettpharmaand GmbH
- United KingdomRubraca 200mg tabletspharmaand GmbH
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Rubraca
- Liechtenstein · Rubraca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/65c6259d-72c2-4fb5-b215-71f0e6981901 GET /v1/drugs/65c6259d-72c2-4fb5-b215-71f0e6981901?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Rukaparib",
"merkevare_id": "ID_1E13C400-1E62-4559-871E-158B0CA07C1E",
"name_form_strength": "Rubraca tab 250 mg",
"prescription_group": "C"
}See everything about rucaparib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.